Myokardia (NASDAQ: MYOK) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Myokardia to similar businesses based on the strength of its institutional ownership, analyst recommendations, dividends, earnings, valuation, risk and profitability.


This table compares Myokardia and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Myokardia -53.49% -14.92% -11.53%
Myokardia Competitors -5,309.53% -218.50% -39.43%

Analyst Ratings

This is a summary of current ratings and recommmendations for Myokardia and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Myokardia 0 0 6 0 3.00
Myokardia Competitors 866 3223 11693 232 2.71

Myokardia presently has a consensus price target of $54.83, indicating a potential upside of 44.11%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.85%. Given Myokardia’s rivals higher probable upside, analysts plainly believe Myokardia has less favorable growth aspects than its rivals.

Valuation and Earnings

This table compares Myokardia and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Myokardia $39.20 million -$13.15 million -50.07
Myokardia Competitors $284.49 million $33.78 million 82.03

Myokardia’s rivals have higher revenue and earnings than Myokardia. Myokardia is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Myokardia has a beta of 4.21, meaning that its share price is 321% more volatile than the S&P 500. Comparatively, Myokardia’s rivals have a beta of 6.02, meaning that their average share price is 502% more volatile than the S&P 500.

Insider and Institutional Ownership

63.6% of Myokardia shares are held by institutional investors. Comparatively, 50.0% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 33.4% of Myokardia shares are held by company insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.


Myokardia beats its rivals on 7 of the 12 factors compared.

Myokardia Company Profile

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.

Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with's FREE daily email newsletter.